Literature DB >> 17786932

Characterization of anti-osteopontin monoclonal antibodies: Binding sensitivity to post-translational modifications.

Christian C Kazanecki1, Aaron J Kowalski, Tony Ding, Susan R Rittling, David T Denhardt.   

Abstract

Osteopontin (OPN) is primarily a secreted phosphoglycoprotein found in a variety of tissues and body fluids. It has a wide range of reported functions, many of which are affected by the degree of post-translational modification (PTM) of the protein. These PTMs include phosphorylation, glycosylation, and cross-linking by transglutaminase. Here we describe the generation of unique monoclonal antibodies raised against recombinant OPN utilizing the OPN knockout mouse. The antibodies exhibit differential binding to OPN produced by different cell lines from the same species, as well to the multiple OPN forms in human urine. Most of the antibodies generated are able to recognize OPN produced by ras-transformed mouse fibroblasts, however only one antibody recognizes the more phosphorylated protein produced by the differentiating pre-osteoblast murine cell line MC3T3E1. Using a novel biopanning procedure combining T7 phage gene fragment display and protein G precipitation, we have epitope-mapped these antibodies. Several of the antibodies bind to regions of the OPN molecule that are phosphorylated, and one binds the region of OPN that is glycosylated. Using phosphorylated and non-phosphorylated peptides, we show that the binding of two antibodies to the C-terminal end of OPN is inhibited by phosphorylation of this region. In addition, these two antibodies are able to inhibit cell adhesion to recombinant and weakly modified OPN. The antibodies described herein may prove useful in determining the presence of modifications at specific sites and for identifying structural forms of OPN. Also, the sensitivity of these antibodies to PTMs suggests that caution must be taken when choosing anti-OPN monoclonal antibodies to detect this highly modified protein. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17786932     DOI: 10.1002/jcb.21487

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  17 in total

Review 1.  Intracellular osteopontin (iOPN) and immunity.

Authors:  Makoto Inoue; Mari L Shinohara
Journal:  Immunol Res       Date:  2011-04       Impact factor: 2.829

2.  Osteopontin, an oxidant stress sensitive cytokine, up-regulates collagen-I via integrin α(V)β(3) engagement and PI3K/pAkt/NFκB signaling.

Authors:  Raquel Urtasun; Aritz Lopategi; Joseph George; Tung-Ming Leung; Yongke Lu; Xiaodong Wang; Xiaodong Ge; Maria Isabel Fiel; Natalia Nieto
Journal:  Hepatology       Date:  2012-02       Impact factor: 17.425

3.  An osteopontin-integrin interaction plays a critical role in directing adipogenesis and osteogenesis by mesenchymal stem cells.

Authors:  Qing Chen; Peishun Shou; Liying Zhang; Chunliang Xu; Chunxing Zheng; Yanyan Han; Wenzhao Li; Yin Huang; Xiaoren Zhang; Changshun Shao; Arthur I Roberts; Arnold B Rabson; Guangwen Ren; Yanyun Zhang; Ying Wang; David T Denhardt; Yufang Shi
Journal:  Stem Cells       Date:  2014-02       Impact factor: 6.277

4.  Thrombin cleavage of osteopontin disrupts a pro-chemotactic sequence for dendritic cells, which is compensated by the release of its pro-chemotactic C-terminal fragment.

Authors:  Zhifei Shao; John Morser; Lawrence L K Leung
Journal:  J Biol Chem       Date:  2014-08-11       Impact factor: 5.157

5.  Further characterization of the target of a potential aptamer biomarker for pancreatic cancer: cyclophilin B and its posttranslational modifications.

Authors:  Partha Ray; Bruce A Sullenger; Rebekah R White
Journal:  Nucleic Acid Ther       Date:  2013-10-23       Impact factor: 5.486

6.  Modulation of infection-mediated migration of neutrophils and CXCR2 trafficking by osteopontin.

Authors:  Rani Singh; Tommy Hui; Aritsune Matsui; Ziyad Allahem; Christopher D Johnston; Montserrat Ruiz-Torruella; Susan R Rittling
Journal:  Immunology       Date:  2016-10-07       Impact factor: 7.397

7.  Effects of osteopontin inhibition on radiosensitivity of MDA-MB-231 breast cancer cells.

Authors:  Antje Hahnel; Henri Wichmann; Matthias Kappler; Matthias Kotzsch; Dirk Vordermark; Helge Taubert; Matthias Bache
Journal:  Radiat Oncol       Date:  2010-09-17       Impact factor: 3.481

8.  Evolution of a histone H4-K16 acetyl-specific DNA aptamer.

Authors:  Berea A R Williams; Liyun Lin; Stuart M Lindsay; John C Chaput
Journal:  J Am Chem Soc       Date:  2009-05-13       Impact factor: 15.419

9.  High calcium concentration and calcium oxalate crystals cause significant inaccuracies in the measurement of urinary osteopontin by enzyme linked immunosorbent assay.

Authors:  Lauren A Thurgood; Phulwinder K Grover; Rosemary Lyons Ryall
Journal:  Urol Res       Date:  2008-05-14

10.  Milk osteopontin, a nutritional approach to prevent alcohol-induced liver injury.

Authors:  Xiaodong Ge; Yongke Lu; Tung-Ming Leung; Esben S Sørensen; Natalia Nieto
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-03-21       Impact factor: 4.052

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.